Anumigilimab clinical trials
Also written CSL324.
How each study uses anumigilimab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the anumigilimab studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
4 studies that test it; most in 2020 (2)
| Year | Studies |
|---|---|
| 2020 | 2 |
| 2022 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 4 · Other 0
Studies
Open first, then newest update. How each study uses anumigilimab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- Safety of Anumigilimab (CSL324) in Adults With Sickle Cell Disease (SCD)RecruitingPhase 2CSL BehringNCT07224360Written as Anumigilimab
- Effects of CSL324 in the Lung After Segmental ChallengeCompletedPhase 1CSL BehringNCT05653713Written as CSL324
- Pharmacokinetics and Safety of Subcutaneous CSL324 in Healthy Japanese and White SubjectsCompletedPhase 1CSL BehringNCT04570267Written as CSL324
- CSL324 in COVID-19WithdrawnPhase 2CSL BehringNCT04519424Written as CSL324
Codes
What other systems call anumigilimab · ClinicalTrials.gg INT016843
- UNII (FDA) IA9ALH5N8DANUMIGILIMABOne source FDA
- NCI Thesaurus C184859AnumigilimabOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | IA9ALH5N8D | ANUMIGILIMAB | One source FDA |
| NCI Thesaurus | C184859 | Anumigilimab | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.